Attached files
| file | filename |
|---|---|
| EX-10.2 - FORM OF PURCHASE AGREEMENT - BIOTRICITY INC. | exhibit10_2.htm |
| EX-10.1 - FORM OF PROMISSORY NOTE - BIOTRICITY INC. | exhibit10_1.htm |
|
UNITED STATES |
SECURITIES AND EXCHANGE COMMISSION |
WASHINGTON, DC 20549 |
|
FORM 8-K |
|
CURRENT REPORT PURSUANT |
TO SECTION 13 OR 15(D) OF THE |
SECURITIES EXCHANGE ACT OF 1934 |
|
Date of report (Date of earliest event reported): January 7, 2019 |
|
BIOTRICITY INC. |
(Exact Name of Registrant as Specified in Its Charter) |
|
|
|
|
|
Nevada |
| 333-201719 |
| 47-2548273 |
(State or Other Jurisdiction of Incorporation or Organization) |
| (Commission File Number) |
| (IRS Employer Identification No.) |
|
|
|
275 Shoreline Drive, Suite 150 Redwood City, California |
| 94065 |
(Address of Principal Executive Offices) |
| (Zip Code) |
Registrant’s Telephone Number, Including Area Code: (650) 832-1626 | ||
| ||
(Former Name or Former Address, if Changed Since Last Report) | ||
1
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
|
o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
|
|
| Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company x |
|
|
| If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x |
2
Item 1.01 Entry into a Material Definitive Agreement.
On January 9, 2019, pursuant to two purchase agreements Biotricity, Inc. (the “Company”) sold to two accredited investors a total of $400,000 in principal amount of notes. The notes are non- convertible, bear an interest rate of 10% per year and mature on January 9, 2020.
Copies of the form of purchase agreement and promissory note are attached hereto as exhibits to this Current Report. The foregoing description of the material terms of the purchase agreement and promissory note are qualified in their entirety by reference by such exhibits.
Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.
The information provided in response to Item 1.01 of this report is incorporated by reference into this Item 2.03.
Item 9.01 Financial Statements and Exhibits.
(d)
Exhibit NO.
Description
3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Date: January 15, 2019
|
|
|
| BIOTRICITY INC. | |
|
|
|
| By: | /s/ John Ayanoglou |
|
| John Ayanoglou |
|
| Chief Financial Officer |
4